Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug and supplement delivery technology, today announced that Kraig Higginson, Interim Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on August 20 at 1:45 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_5UneWjXKTOuzgbB4wpeByg
One-on-One Meetings
Aspire will also host virtual one-on-ones with investors on Wednesday, August 20 and Thursday, August 21, 2025. To register for the presentation or one-on ones, visit https://sidoti.com/events.
A replay of the presentation will be available on the investor relations section of Aspire’s website at https://ir.aspirebiolabs.com/events/
About Aspire Biopharma, Inc.
Aspire Biopharma has developed a patent-pending disruptive technology that can deliver supplements and drugs to the body rapidly and precisely with less negative impact to the system by going directly to the bloodstream and avoiding the gastrointestinal tract. For more information, please visit www.aspirebiolabs.com.
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
SOLANA BEACH, Calif.--(BUSINESS WIRE)--Macnica Americas today announced the appointment of Nestor Amaya as Vice President…
Every year, millions of Americans who miss their tax filing deadlines assume the IRS is…
Genius Sports has deployed its cutting-edge data and AI platform GeniusIQ in every Liga MX…
Starting June 4, My Best Buy Plus™ and My Best Buy Total™ members will automatically…
New platform combines 17 years of proprietary compliance data with direct access to credentialed experts,…
Translational Data Inform a Scalable, Noninvasive Test Designed to Identify Treatment-Eligible Patients and Enable Longitudinal…